NA
RXRX icon

NewEdge Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

NewEdge Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115K Buy
31,395
+1,882
+6% +$6.27K ﹤0.01% 2907
2026
Q1 		$90.6K Sell
29,513
-4,244
-13% -$16.4K ﹤0.01% 2785
2025
Q4 		$138K Buy
33,757
+20,226
+149% +$100K ﹤0.01% 2682
2025
Q3 		$66K Buy
13,531
+2,470
+22% +$13K ﹤0.01% 2742
2025
Q2 		$56K Buy
11,061
+2,428
+28% +$11.9K ﹤0.01% 2630
2025
Q1 		$45.7K Buy
8,633
+786
+10% +$5.73K ﹤0.01% 2579
2024
Q4 		$53K Buy
7,847
+2,387
+44% +$16K ﹤0.01% 2509
2024
Q3 		$36K Buy
5,460
+2,860
+110% +$20.5K ﹤0.01% 2535
2024
Q2 		$19.5K Buy
2,600
+500
+24% +$4.36K ﹤0.01% 2635
2024
Q1 		$20.9K Hold
2,100
– – ﹤0.01% 2614
2023
Q4 		$20.7K Buy
2,100
+464
+28% +$3.31K ﹤0.01% 2563
2023
Q3 		$12.5K Buy
+1,636
New +$16.3K ﹤0.01% 2502

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

NewEdge Advisors's RXRX Position: Q2 2026 in Review

NewEdge Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 6.4% in Q2 2026, buying an estimated $6.27K and bringing the position to 31,395 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #2907.

NewEdge Advisors first reported a position in RXRX in Q3 2023 and has held it in 12 quarters since. The position peaked at $138K in Q4 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • NewEdge Advisors held 31,395 shares of Recursion Pharmaceuticals worth $115K as of Q2 2026.
  • NewEdge Advisors bought 1,882 Recursion Pharmaceuticals shares in Q2 2026, an estimated $6.27K.
  • Recursion Pharmaceuticals made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #2907 holding.
  • NewEdge Advisors first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • NewEdge Advisors's Recursion Pharmaceuticals position peaked at $138K in Q4 2025.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.